Results 71 to 80 of about 81,893,885 (284)

Retrospective Analysis of Donor Lymphocyte Infusions in Pediatric Patients With Mixed Chimerism After Hematopoietic Stem Cell Transplantation

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Allogeneic hematopoietic stem cell transplantation (alloHSCT) is an essential therapy for several malignant and nonmalignant diseases, but relapse and graft loss remain the principal threats to its success. Routine monitoring of chimerism and minimal residual disease (MRD) enables early detection of imminent recurrence and guides ...
Carmen Junk   +10 more
wiley   +1 more source

The Role of gp130 Cytokines in Tuberculosis

open access: yesCells, 2020
Protective immune responses to Mycobacterium tuberculosis (Mtb) infection substantially depend on a delicate balance within cytokine networks. Thus, immunosuppressive therapy by cytokine blockers, as successfully used in the management of various chronic
Kristina Ritter   +2 more
doaj   +1 more source

IL-6 Receptor Independent Stimulation of Human gp130 by Viral IL-6 [PDF]

open access: yesThe Journal of Immunology, 2000
Abstract The genome of human herpes virus 8, which is associated with Kaposi’s sarcoma, encodes proteins with similarities to cytokines and chemokines including a homologue of IL-6. Although the function of these viral proteins is unclear, they might have the potential to modulate the immune system. For viral IL-6 (vIL-6), it has been
J, Müllberg   +9 more
openaire   +2 more sources

IL-6 ICC P2 100x

open access: yes, 2022
Expression of IL-6 in treatment group (Azadirachta indica varian Philippines) of HepG2 model hepatocellular carcinoma by immunohistochemistry (100x magnification)
Ricadonna Raissa (12081878)
core   +1 more source

Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Idiopathic multicentric Castleman disease (iMCD) is a potentially fatal immunologic disorder marked by widespread lymphadenopathy and inflammation. Siltuximab, an interleukin‐6 (IL‐6) inhibitor, is the only FDA‐approved treatment for adult patients with iMCD.
Bridget Austin   +17 more
wiley   +1 more source

IL-1β regulated the expression of TNF-α, IL-6 and IL-8.

open access: yes, 2023
The expression levels of TNF-α, IL-6 and IL-8 were significantly increased after CSE administration, which were downregulated upon IL-1β knockdown.
Rui Min (4039946)   +6 more
core   +1 more source

The Impact of the COVID‐19 Pandemic on Childhood Cancer Survival: A Population‐Based Assessment of Survival Patterns Between 2015 and 2023 in Germany

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Numerous international studies have reported declines in new cancer diagnoses, delayed diagnoses and disruptions in cancer treatment following the implementation of COVID‐19 pandemic public health measures, raising concerns that these effects may ultimately contribute to increased cancer mortality.
Friederike Erdmann   +8 more
wiley   +1 more source

Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo [PDF]

open access: yesRheumatology, 2014
Reports on the regulation of neutrophil function by IL-6 are often conflicting. Therapeutic inhibition of IL-6 in RA is associated with occasional neutropenia, but the mechanisms underlying this observation are poorly understood. This study investigated interactions between IL-6, the anti-IL-6 receptor agent tocilizumab (TCZ) and neutrophils in vitro ...
Helen L, Wright   +3 more
openaire   +2 more sources

IL-6 IHC PC 1000x

open access: yes, 2022
Expression of IL-6 in positive control group hepar tissue of rattus norvegicus model hepatocellular carcinoma by immunohistochemistry (1000x magnification)
Ricadonna Raissa (12081878)
core   +1 more source

Referral Patterns and Diagnostic Timeliness in Pediatric Cancer: A Hospital‐Based Study in Indonesia

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Timely diagnosis and treatment are critical for improving survival among children with cancer. In low‐ and middle‐income countries (LMICs), delays are common and may be influenced by fragmented referral pathways and diagnostic limitations.
Nur Melani Sari   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy